AH1

AH1 is a MHC class I-restricted tumor-specific antigenic peptide that can be presented by the murine MHC class I molecule Ld. AH1 is derived from the envelope protein (gp70) of the endogenous ecotropic murine leukemia virus (MuLV) in mice. AH1 acts as an immunodominant CTL epitope in CT26 colon carcinoma. Additionally, AH1 is also an immunodominant CTL target for TS/A murine mammary adenocarcinoma, and its specific CTLs can mediate the killing and rejection of this tumor[1][2].

Product Specifications

CAS Number

[181272-91-3]

UNSPSC

12352209

Target

MHC

Type

Peptides

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ah1.html

Purity

99.16

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](C(C)C)C(N[C@H](C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)CC3=CN=CN3)=O)CC4=CC=C(C=C4)O)=O)=O)NC([C@H](CO)NC([C@H]5N(CCC5)C([C@@H](N)CO)=O)=O)=O

Molecular Formula

C54H70N12O15

Molecular Weight

1127.21

References & Citations

[1]M Toda, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999 Feb 10;10 (3) :385-93.|[2]Antonio Rosato, et al. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res. 2003 May 1;63 (9) :2158-63.